uMRD-negative status linked to recurrence-free outcomes with nadofaragene firadenovec in NMIBC
Jason Scovell
Advertisement
Articles by Jason Scovell
Surgery after neoadjuvant immune checkpoint inhibitor therapy for renal cell carcinoma is safe even in challenging surgical cases, according to Jason Scovell, MD.
Advertisement
Latest Updated Articles
Nadofaragene Firadenovec Results in uMRD-Negative Status in NMBICJanuary 28th 2024
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
2
Precision Medicine and the “Slow Death” of Transplant in Lymphoma
3
TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i
4
FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
5